Abstract
Purpose
Statins are among the most frequently prescribed medications internationally. Older people are commonly prescribed multiple medications and are at an increased risk of drug-drug interactions, including statin-drug interactions. The aim of this study was to conduct a systematic review of current evidence on the prevalence of statin-drug interactions in older people.
Methods
A systematic search of observational studies in Embase, Medline, and PubMed was conducted. Articles were included if they were published in English during the period July 2000–July 2014 and reported on the prevalence of statin-drug interactions in people over 65 years of age. Two reviewers independently assessed the articles for eligibility and extracted the data.
Results
The search returned 1556 eligible articles. A total of 19 articles met the inclusion criteria. In studies (n = 7) that focused on statin users only, the prevalence of potential statin-drug interactions assessed using different measures ranged from 0.19 to 33.0 %. In studies that examined drug interactions across a population of both statin users and non-users (n = 12), the prevalence of potential statin-drug interactions ranged from 0.1 to 7.1 % (n = 8), and the prevalence of clinically relevant statin-drug interactions ranged from 1.5 to 4 % (n = 4).
Conclusions
Current published evidence suggests substantial variations in the prevalence of statin-drug interactions and their clinical relevance. Further studies are necessary to provide a better understanding of the prevalence of clinically significant statin-drug interactions, the medications most frequently contributing to statin-drug interactions, and impact on relevant clinical outcomes in older people.
Similar content being viewed by others
References
Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J (2012) A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 196:50–53
Elliott RA (2006) Problems with medication use in the elderly: an Australian perspective. J Pharm Pract 36:58–66
Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C (2013) Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 47:324–332
Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918
Gnjidic D, Johnell K (2013) Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol 40:320–325
Hilmer SN, McLachlan AJ, Le Couteur DG (2007) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21:217–230
Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9:364–377
Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M (2012) Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 108:216–227
Lo-Ciganic WH, Boudreau RM, Gray SL et al (2013) Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother 47:984–992
Gnjidic D, Le Couteur DG, Blyth FM et al (2013) Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 3(3):e002333
Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ (2008) Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51:37–45
Roberts CG, Guallar E, Rodriguez A (2007) Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 62:879–887
Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278
Bellosta S, Corsini A (2012) Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 11:933–946
Ho CKM, Walker SW (2011) Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf 3:35–46
Bottorff MB (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C–31C
Corsini A, Ceska R (2011) Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 27:1551–1562
Cabrera MA, Dip RM, Furlan MO, Rodrigues SL (2009) Use of drugs that act on the cytochrome P450 system in the elderly. Clinics (Sao Paulo, Brazil) 64:273–278
Bakhai A, Rigney U, Hollis S, Emmas C (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 21:485–493
Ming EE, Davidson MH, Gandhi SK et al (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2:453–463
Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V, group U (2005) Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61:615–620
Einarson TR, Metge CJ, Iskedjian M, Mukherjee J (2002) An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 24:2126–2136
Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24:429–440
Karimi S, Hough A, Beckey C, Parra D (2010) Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm 16:472–481
Petropoulos JB, Bello-Quintero CE (2004) Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. J Manag Care Pharm 10:239–243
Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D (2010) The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32:815–821
Ghibelli S, Marengoni A, Djade CD et al (2013) Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (intercheck registered trademark). Drugs Aging 30:821–828
Halvorsen KH, Granas AG, Engeland A, Ruths S (2012) Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiol Drug Saf 21:929–936
Kerr KP, Mate KE, Magin PJ et al (2014) The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther 39:383–389
Lao CK, Ho SC, Chan KK, Tou CF, Tong HHY, Chan A (2013) Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. Int J Clin Pharm 35:805–812
Lea M, Rognan SE, Koristovic R, Wyller TB, Molden E (2013) Severity and management of drug-drug interactions in acute geriatric patients. Drugs Aging 30:721–727
Marcum ZA, Driessen J, Thorpe CT, Gellad WF, Donohue JM (2014) Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with medicare part D. J Am Geriatr Soc 62:244–252
Pasina L, Djade CD, Nobili A et al (2013) Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 22:1054–1060
Popovic B, Quadranti NR, Matanovic SM et al (2014) Potentially inappropriate prescribing in elderly outpatients in Croatia. Eur J Clin Pharmacol 70:737–744
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878
Roughead EE, Kalisch LM, Barratt JD, Gilbert AL (2010) Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol 70:252–257
Dudash K, Negri G, Baccarini S, Rabinowitz C, Maio V (2011) Prevalence and predictors of potentially significant drug-drug interactions in the elderly. Value Health 14:A7
Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marin-Gil R, Villacorta-Linaza P (2012) Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 34:807–817
Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641–651
Hassan FA, Taylor DM, Leow FHP, Doolan G, Knott JC (2006) Potential interactions between drugs taken by emergency department patients of an Australian hospital. J Pharm Pract 36:266–270
Florentin M, Elisaf MS (2012) Simvastatin interactions with other drugs. Expert Opin Drug Saf 11:439–444
Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581
Ronaldson KJ, O'Shea JM, Boyd IW (2006) Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 29:1061–1067
Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63:709–714
Vonbach P, Dubied A, Krahenbuhl S, Beer JH (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367–374
Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30:21–37
Thai M, Hilmer S, Pearson SA, Reeve E, Gnjidic D (2015) Prevalence of potential and clinically relevant statin-drug interactions in frail and robust older inpatients. Drugs Aging 32:849–856
Acknowledgments
Danijela Gnjidic is supported by a National Health and Medical Research Early Career Fellowship. Sallie-Anne Pearson is a Cancer Institute NSW Career Development Fellow. Emily Reeve is employed by the NHMRC Cognitive Decline Partnership Centre which receives financial support from the Australian National Health and Medical Research Council and partners Alzheimer’s Australia and aged care providers HammondCare, HelpingHand, and Brightwater.
Author contributions
All authors contributed to conception and planning of the article. MT, ER, KQ, and DG contributed to manuscript acquisition, analysis, and interpretation of the data. All authors contributed to paper drafting, critical revision, and have approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thai, M., Reeve, E., Hilmer, S.N. et al. Prevalence of statin-drug interactions in older people: a systematic review. Eur J Clin Pharmacol 72, 513–521 (2016). https://doi.org/10.1007/s00228-016-2011-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-016-2011-7